Embed Size (px)
Citation preview
A D V A N C I N G I N N O V A T I O N I N H E A L T H C A R E
Partners Innovation Fund
Partners HealthCare
July 2017
P A R T N E R S I N N O V A T I O N F U N DIn Brief
Capitalization $165M fund
$100 million core fund capitalized by MGH and BWH
$65 million strategic fund capitalized by pharma and other strategic investors
Focus Medical innovations discovered and developed at Partners institutions
Strategy Capital should accelerate breakthrough technologies in healthcare
Experienced innovators, executives, entrepreneurs, and investors
Deep scientific domain expertise
Established track record of invention, new venture conception, and company building
Proven value creation
P I F I N V E S T M E N T T E A M
Meredith Fisher, PhDPartner
Life Science Investor & Scientist
Director, Bracebridge Capital
Sr. Director of Tech & Bus Devel.,
PureTech Ventures/ Enlight
Biosciences
Scientist, Idenix & Anadys
Pharma.
Investments: ImmuneXcite &
Lyndra.
FOCUS AREAS: therapeutics and
devices
Carl Berke, PhDPartner
Innovator & Strategy Consultant
Partner, Integral/Analysis Group
R&D Director, Polaroid & Hygeia
Founder & Director, Mass
Medical Angels
Licensing Officer, MIT
Investments: Annovation, QPID,
lifeIMAGE, Sebacia &
Syntimmune
FOCUS AREAS: materials,
devices, diagnostics,
HIT/software and chemistries
Jay KnowlesPartner
BD Executive & CEO
20+ years in business
development
CEO, X-BODY (acquired by
Juno)
BD Exec, Novartis and Vertex
Investments: Abcuro, Editas,
Denali, Keros, LTI, Quartet &
Tilos.
FOCUS AREAS: therapeutics
Roger KittermanManaging Partner
Entrepreneur & Venture
Capitalist
20+ years venture experience
Co-Founder, Mass Medical
Angels
Partner, Mi3 Venture Partners
Investments: CoStim, Adheron,
Spero, RaNA and Magenta.
FOCUS AREAS: therapeutics
Barbara Fox
CEO, Tilos Therapeutics, Inc.
John Ripple
CEO, Ensemble Therapeutics
Experienced Early-Stage
Industry Leaders
Executive Leadership
Operating Experience
Business Development
Scientific Discovery
Raising Venture Capital
E I R P R O G R A M : G R O W I N G O P E R A T I O N A L E X P E R I E N C E
20+ years biotechnology experience
• CEO, Avaxia Biologics
• EIR, Oxford Bioscience
• President, Founder & CSO,
Recovery Pharmaceuticals
• Assoc. Professor of Medicine, U of
Maryland School of Medicine
PhD Chemistry, MIT
BA Chemistry, Bryn Mawr College
20+ years biopharma experience
• CEO, Permeon Biologics
• CEO, Virdante Pharmaceuticals
• CEO, Syntonix Pharmaceuticals
• BD Exec, Wyeth/Genetics Institute
• Advisor, MIT Deshpande Center
MBA, Harvard Business School
BS Mechanical Engineering, Bucknell
University
P I F I N V E S T M E N T P I P E L I N E
P A R T N E R S H E A L T H C A R E S Y S T E M
Pre-clinical, clinical, post-approval and observational research
Longitudinal patient data: intervention, cost, outcomes, patient
behavior and population management
Tissue and other bio-repositories
Big Data and connected health
P R O C E S S O F T E C H N O L O G Y I N N O V A T I O N
A N D C O M P A N Y C O N C E P T I O N
Annual Pipeline
>10,000 Scientific
Publications
Annually
> 500 Invention
Disclosures
>250 Patent
Filings
>50 Qualified
Opportunities
3-5 NewCo
Investments
P I F : A C T I V E P O R T F O L I O
Name Start Sector Description
Abcuro* 2016 Therapeutics Immuno-oncology and autoimmune therapy
ImmuneXcite* 2016 Therapeutics Immunotherapy platform targeting innate immune response
Keros* 2016 Therapeutics Treatment of rare muscle disorders
Lyndra* 2016 Therapeutics Extended release technology for orally administrated drugs
Magenta* 2016 Therapeutics Stem cell therapeutics platform
Tilos* 2016 Therapeutics Immunotherapy based on repression of T regs
Denali 2015 Therapeutics Neurodegenerative therapeutics
LTI 2014 Therapeutics Neurodegenerative therapies
Quartet 2014 Therapeutics Treatments for neuropathic pain
Syntimmune 2014 Therapeutics Treatment for autoimmune disorders
Spero 2013 Therapeutics Novel anti-infectives
RaNA 2011 Therapeutics RNA-based therapies
Sebacia 2010 Medical Devices Photoactivated topical treatment for acne
lifeIMAGE 2009 HIT Cloud based diagnostic image exchange
P I F H A S S T R O N G S Y N D I C A T E P A R T N E R S
$1 Billion
Equity co-investment
by syndicate partners
in PIF portfolio
companies
Str
ate
gic
Part
ners
Established relationships with top tier venture capital and strategic industry partners
P O R T F O L I O C O M P A N Y T H E R A P E U T I C A S S E T S -
C L I N I C A L D E V E L O P M E N T
Current Company Portfolio Company Product Late Preclinical Phase I Phase II Indication
Magenta Magenta MGTA-456Cord Blood Transplant
Medicines Company Annovation ABP-700 Anesthesia
Novartis CoStim PDR-001 Oncology
Roche Adheron RG-6125 Rheumatoid Arthritis
Syntimmune Syntimmune SYNT-001 Immunology
Denali Denali RIP1 Neurodegeneration
Novartis CoStim LAG-525 Oncology
Novartis CoStim MBG-453 Oncology
Novartis CoStim FAZ-053 Oncology
Spero Spero SPR-741 Infectious Disease
Keros Keros FOP
LTI LTI Parkinson's
Lyndra Lyndra Neuro
Quartet Quartet Pain
Translate (RaNA) Translate (RaNA) Cystic Fibrosis
L I Q U I D I T Y E V E N T S
CoStim - record breaking return for an early-stage biotech company (24x if all
milestones are reached)
Editas – Market leader in CRISPR genome editing (IPO Feb 2016)
Annovation - game-changing anesthetic agent representing most significant new
technology in 30 years if approved
Company Description
Event
(Year) Acquirer / IPO
Enterprise
Value
Novel treatments for
fibrotic diseases2015 $580M
Safer Anesthesia 2015 Undisclosed
Immuno-oncology
drugs 2014 Undisclosed
Gene Editing 2016IPO (NASDAQ:
EDIT)$639M
EHR intelligence
software 2016 Undisclosed
Lysosome-based
genetic disorders2017 Undisclosed
H O W T O E N G A G E W I T H P I F
• HOW TO ACCESS US: Contact us directly or work through Market Sector
Leader or Licensing Manager
• WHAT WE EXPECT: First meetings focus on science/technology, medical
need and proposed development path
• WHAT WE DON’T EXPECT: No expectation that PI will have developed
business plan or an established a team/CEO
• OUR PROCESS: Collaborative! PIF works with scientific founder(s) to build
a plan, team and investment syndicate
Partners Innovation Fund Partners HealthCare
215 First Street, Suite 500
Cambridge, MA 02142
857-307-2400
innovation.partners.org
Advancing Innovation in Health Care
